Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease.
- Author:
Tadakazu HISAMATSU
1
;
Mari HAYASHIDA
Author Information
- Publication Type:Review
- Keywords: Intestinal Behçet's disease; Anti-TNF-α mAb; Mucosal healing
- MeSH: Adrenal Cortex Hormones; Antibodies, Monoclonal; Inflammatory Bowel Diseases; Mesalamine; Necrosis; Quality of Life; Stomatitis, Aphthous; Tumor Necrosis Factor-alpha
- From:Intestinal Research 2017;15(3):318-327
- CountryRepublic of Korea
- Language:English
- Abstract: Behçet's disease (BD) is a chronic relapsing disease involving multiple organ systems. BD is characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. It is widely recognized that the presence of intestinal lesions may be a poor prognostic factor in intestinal BD, increasing the risk of surgery and decreasing the quality of life. Despite this, the management of intestinal BD has not been standardized. Empirical therapies including 5-aminosalicylic acid and corticosteroids have been used anecdotally to treat intestinal BD, but recent studies have provided evidence for the efficacy of anti-tumor necrosis factor α monoclonal antibodies. The development of agents targeting tumor necrosis factor α continues, it seems likely that they will change the therapeutic strategy and clinical outcomes of intestinal BD and inflammatory bowel disease. Monitoring disease activity such as endoscopic evaluation will become more important to obtain better outcomes. Here, we review current and future perspectives in the treatment and outcomes of intestinal BD.
